			Home About us Contact

Platinum Salts (platinum + salt)

Distribution by Scientific Domains

Medical Sciences	75%

Selected Abstracts

Synthesis of High-Surface-Area Platinum Nanotubes Using a Viral Template

ADVANCED FUNCTIONAL MATERIALS, Issue 8 2010
. Górzny, Marcin
Abstract A novel method for the synthesis of high-active-surface-area, platinum,tobacco mosaic virus (Pt,TMV) nanotubes is presented. A platinum salt is reduced to its metallic form on the external surface of a rod-shaped TMV by methanol, which serves as a solvent and reductant simultaneously. It was found that for the same Pt loading the Pt,TMV nanotubes had an electrochemically active surface area between 4 to 8 times larger than similarly sized Pt nanoparticles. A Pt,TMV catalyst displays greater stability in acidic conditions than those based on nanoparticles. When used as a catalyst for methanol oxidation, these Pt nanotubes display a 65% increase in catalytic mass activity compared to that based on Pt nanoparticles. [source]

Occupational immediate-type asthma and rhinitis due to rhodium salts

AMERICAN JOURNAL OF INDUSTRIAL MEDICINE, Issue 1 2010
Rolf Merget MD
Abstract Background Whereas platinum salts are well known occupational allergens, rhodium salts have not been identified as inhalative sensitizing substances. Methods A 27-year-old atopic operator of an electroplating plant developed work-related shortness of breath and runny nose with sneezing after exposure to rhodium salts. Quantitative skin prick tests (SPT) and bronchial challenge tests with a dosimeter protocol were performed with quadrupling doses of the sodium chloride salts of rhodium (Na3RhCl6) and platinum (Na2PtCl6). Results The patient showed positive SPT reactions and positive bronchial immediate-type reactions with rhodium and platinum salts. Sensitivity to rhodium salt was much higher than to platinum salt; the molar concentrations differed by a factor of 256 in SPT and a factor of 16 in bronchial challenges. Conclusions Rhodium salts should be considered as occupational immediate-type allergens. Am. J. Ind. Med. 53:42,46. 2010. © 2009 Wiley-Liss, Inc. [source]

P03 Type-I and -IV hypersensitivity to platinum salts

CONTACT DERMATITIS, Issue 3 2004
Willeke Kamphof
A 28-year-old female analytical chemist visited our patch test clinic with initially complaints of severe hand dermatitis. Later on she developed rhinitis, bronchial asthma and tightness of the chest. The complaints seemed work related: her condition improved during holidays and on sick leaves. She worked in a laboratory with several platinum salts and used different kinds of gloves (latex, nitril, etc.). Methods:, Patch tests were performed with the European Standard series and prick tests with common inhalant allergens. Patch-, prick- and open patch tests were carried out with various aqueous dilutions of platinum chloride (PtCl2). Results:, Patch tests with 0.01,2% PtCl2 were positive on day 2, 3 and 6, and at 0.001% a follicular reaction was found. The prick-test was already positive at the lowest concentration tested (0.001%). The open patch test, carried out retro-auricular, showed a positive reaction at 1 and 2% PtCl2 after 20 min. Controls in healthy volunteers (n = 5) were all negative. Discussion:, It is well known that platinum salts can cause type-I hypersensitivity reactions like allergic rhinitis, conjunctivitis, bronchial asthma and urticaria, also referred to as platinosis. Contact dermatitis to platinum salts, however, is very rare. In our patch test clinic, 78 patients were tested between 1987 and 2001 with PtCl2 2%. Only 2 women showed a positive patch test for PtCl2. The patient presented here, stopped working with platinum salts and recovered from all complaints. We interpret our case as occupational type-I and type-IV hypersensitivity to platinum salts with mucosal and dermal manifestations. [source]

Platinum Nanoparticles Supported on Ionic Liquid-Modified Magnetic Nanoparticles: Selective Hydrogenation Catalysts

ADVANCED SYNTHESIS & CATALYSIS (PREVIOUSLY: JOURNAL FUER PRAKTISCHE CHEMIE), Issue 13 2007
Raed Abu-Reziq
Abstract A method for supporting platinum nanoparticles on magnetite nanoparticles is described. The method requires modification of the surface of the magnetic nanoparticles with ionic liquid groups. Before modification, the magnetic nanoparticles are not stable and easily aggregate and, after modification, the magnetite nanoparticles become highly stable and soluble in polar or non-polar organic solvents depending on the alkyl group of the linked ionic liquids. The supporting of platinum nanoparticles on the modified magnetic nanoparticles was achieved by adsorbing platinum salts (K2PtCl4) on the surface of the magnetite nanoparticles via ion exchange with the linked ionic liquid groups and then reducing them by hydrazine. The supported platinum nanoparticles were applied in the catalytic hydrogenation of alkynes in which cis -alkenes were selectively produced, and in the hydrogenation of ,,,-unsaturated aldehydes where the allyl alcohols were obtained as the exclusive products. The new catalyst can be easily separated from the reaction mixtures by applying an external magnetic field and recycled. [source]

Occupational immediate-type asthma and rhinitis due to rhodium salts

Clinical Experience with Trastuzumab (Herceptin)

THE BREAST JOURNAL, Issue 6 2003
Charles L. Vogel MD
Abstract: Trastuzumab is a humanized monoclonal antibody against the epidermal growth factor family oncogene, Her-2/neu. It has revolutionized therapy for the 15,20% of patients with metastatic breast cancer whose tumors have gene amplification for Her-2/neu. Results of clinical trials with single agent trastuzumab and in combination with paclitaxel, docetaxel, vinorelbine, gemcitabine and platinum salts have been encouraging. Durable remissions in excess of 5 years have occasionally been reported. Subjectively the side effect profile of this novel, targeted therapy, has been mild. Cardiac toxicity, while reported in combination regimens with anthracyclines tend to be easily manageable and not absolute contradictions to continuation of trastuzumab. Outside of clinical trials, however, anthracycline/trastuzumab combinations should be avoided. Preliminary results of trials with various combinations of chemotherapeutic agents have been promising while combinations with hormonal and other biologic therapy are ongoing. Trastuzumab is an exciting new monoclonal antibody with interesting anti-tumor activity in patients with Her-2/neu gene amplified breast cancer. We look forward to ongoing clinical trials combining trastuzumab with a broad array of other chemotherapeutic, hormonal and biological agents. [source]